Methods for determining whether a patient is hipercoagulu00e1vel, hipocoagulu00e1vel or normal, to evaluate the coagulation system in a test specimen.To detect defects on the phase propagation and / or amplification in the coagulation system of a test specimen, to monitor a pharmaceutical therapy antithrombotic or pro coagulant.To evaluate the efficacy of a pharmaceutical product antithrombotic or pro coagulant, and to assess the haemostatic potential of a sample

摘要

Methods to determine if a patient is hipercoagulu00e1vel, hipocoagulu00e1vel or normal, to evaluate the coagulation system in a test specimen.To detect defects on the phase propagation and / or amplification in the coagulation system of a test specimen, to monitor a pharmaceutical therapy antithrombotic or pro coagulant.To evaluate the efficacy of a pharmaceutical product antithrombotic or pro coagulant, and to assess the haemostatic potential of a sample.A method is disclosed for determining if a patient is hipercoagulu00e1vel, hipocoagulu00e1vel or normal.The test involves providing a test specimen of the patient and initiate coagulation in the sample in the presence of an activator.That is added to the sample in a quantity that will result in the tenase fibrin dependent intrinsic.After the formation of the polymerization of fibrin dependent on the intrinsic tenase is monitored during a time so as to derive a profile dependent on the time.With the results of monitoring the polymerization of fibrin by determining if the patient is hipercoagulu00e1vel, normal or hipocoagulu00e1vel.The coagulation activator is added in a quantity that triggers a burst of thrombin that is dependent on the stage of spreading and ways of amplification.In this way, a single test can assess the haemostatic potential of a sample.